Efficacy and Safety of Long Term Brentuximab Vedotin Therapy and Retreatment in an AIDS Patient Affected by Refractory/Relapsed Anaplastic Large Cell Lymphoma: Case Report and Literature Review
نویسندگان
چکیده
Lymphoma is the most common type of cancer in patients infected with HIV despite of the introduction of the antiretroviral therapy. Brentuximab Vedotin (BV) is an anti-CD30 antibody-drug conjugate, which has been approved for the treatment of relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). However, fewer data are available on the role of the BV in the treatment of HIV-CD30+ lymphomas and of its impact on outcomes. We describe the first case of retreatment with BV in a HIV patient with ALCL, ALKwho relapsed after a complete response to a previous BV treatment.
منابع مشابه
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was recently approved for the treatment of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Administration. In the present study, we report the experience of the German Hodgkin Study Group with brentuximab vedotin as single agent in 45 patients with refractory or relapsed CD30(+) Hodgkin lymphoma ...
متن کاملHighlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition.
SUMMARY Three-Year Survival Results From an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Updated survival results were presented from a multicenter, open-label, phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic ALCL (Abstract 1809). The trial had enrolled 58 patients, with a media...
متن کاملTargeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
Despite the relative success of chemotherapy for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), novel therapeutic agents are needed for refractory or relapsed patients. Targeted immunotherapy has emerged as a novel treatment option for these patients. Although unconjugated anti-cluster of differentiation (CD)30 antibodies showed minimal antitumor activity in early cli...
متن کاملCombination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T-cell lymphomas, which is characterized by large pleomorphic cells with strong expression of CD30. Translocations involving ALK, the anaplastic lymphoma kinase gene, are associated with a favorable clinical outcome. Such ALK-positive ALCLs are usually responsive to a multidrug chemotherapy with C...
متن کاملBrentuximab Vedotin in CD30+ Lymphomas
Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017